Xiaobo Huang

Dr. Xiaobo Huang

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in The Breast
Verified
Journal Article
Open access
ZYZhuanbo Yang
Zhuanbo Yang
XLXiaowen Lan
Xiaowen Lan
ZHZhou Huang
Zhou Huang
YYYong Yang
Yong Yang
YTYu Tang
Yu Tang
SWShulian Wang
Shulian Wang
To develop a nomogram for predicting the possibility of four or more positive nodes in breast cancer patients with 1–3 positive sentinel lymph nodes (SLN). Retrospective analysis of data of patients from two institutions was conducted. The inclusion criteria were: invasive breast cancer; clinically node negative; received lumpectomy or mastectomy plus SLN biopsy followed by axillary lymph node dissection (ALND); and pathologically confirmed T1-2 tumor, with 1–3 positive SLNs. Patients from one institution formed the training group and patients from the other the validation group. Univariate and multivariate analyses were performed to identify the predictors of four or more positive nodes. These predictors were used to build the nomogram. The area under the receiver operating characteristic curve (AUC) was calculated to assess the accuracy of the model. Of the 1480 patients (966 patients in the training group, 514 in the validation group), 306 (20.7%) had four or more positive nodes. Multivariate stepwise logistic regression showed number of positive (p < .001) and negative SLN (p < .001), extracapsular extension (p < .001), pT stage (p = .016), and tumor location in outer upper quadrant (p = .031) to be independent predictors of four or more positive nodes. The nomogram was built using these five factors. The AUC was 0.845 in the training group and 0.804 in the validation group. The proposed nomogram appears to accurately estimate the likelihood of four or more positive nodes and could help radiation oncologists to decide on use of regional nodal irradiation (RNI) for breast cancer patients with 1–3 positive nodes but no ALND.

4 September 2019 in Journal of Applied Clinical Medical Physics
Verified
Journal Article
Open access
PDF file
JHJiang‐Hua Huang
Jiang‐Hua Huang
XWXiu‐Xiu Wu
Xiu‐Xiu Wu
XLXiao Lin
Xiao Lin
JSJun‐Tian Shi
Jun‐Tian Shi
YMYu‐Jia Ma
Yu‐Jia Ma
XHXiaobo Huang
Xiaobo Huang
Purpose: To investigate the fixed‐jaw intensity‐modulated radiotherapy (F‐IMRT) and tangential partial volumetric modulated arc therapy (tP‐VMAT) treatment plans for synchronous bilateral breast cancer (SBBC).Materials and method: Twelve SBBC patients with pTis‐2N0M0 stages who underwent whole‐breast irradiation after breast‐conserving surgery were planned with F‐IMRT and tP‐VMAT techniques prescribing 42.56 Gy (2.66 Gy*16f) to the breast. The F‐IMRT used 8‐12 jaw‐fixed tangential fields with single (sF‐IMRT) or two (F‐IMRT) isocenters located under the sternum or in the center of the left and right planning target volumes (PTVs), and tP‐VMAT used 4 tangential partial arcs with two isocenters located in the center of the left and right PTVs. Plan evaluation was based on dose‐volume histogram (DVH) analysis. Dosimetric parameters were calculated to evaluate plan quality; total monitor units (MUs), and the gamma analysis for patient‐specific quality assurance (QA) were also evaluated.Results: For PTVs, the three plans had similar Dmean and conformity index (CI) values. F‐IMRT showed a slightly better target coverage according to the V100% values and demonstrated an obvious reduction in V105% and Dmax compared with the values observed for sF‐IMRT and tP‐VMAT. Compared with tP‐VMAT, sF‐IMRT was slightly better in terms of V100%, V105% and Dmax. In addition, F‐IMRT achieved the best homogeneity index (HI) values for PTVs. Concerning healthy tissue, tP‐VMAT had an advantage in minimizing the high dose volume. The MUs of the tP‐VMAT plan were decreased approximately 1.45 and 1 times compared with the sF‐IMRT and F‐IMRT plans, respectively, and all plans passed QA. For the lungs, heart and liver, F‐IMRT achieved the smallest values in terms of Dmean and showed a significant difference compared with tP‐VMAT. Simultaneously, sF‐IMRT was also superior to tP‐VMAT. For the coronary artery, tP‐VMAT achieved the lowest Dmean, while the value for F‐IMRT was 2.24% lower compared with sF‐IMRT. For all organs at risk (OARs), tP‐VMAT was superior at the high dose level. In contrast, sF‐IMRT and F‐IMRT were obviously superior at the low dose level. The sF‐IMRT and F‐IMRT plans showed consistent trends.Conclusion: All treatment plans for the provided techniques were of high quality and feasible for SBBC patients. However, we recommend F‐IMRT with a single isocenter as a priority technique because of the tremendous advantage of local hot spot control in PTVs and the reduced dose to OARs at low dose levels. When the irradiated dose to the lungs and heart exceed the clinical restriction, two isocenter F‐IMRT can be used to maximize OAR sparing. Additionally, tP‐VMAT can be adopted for improving cold spots in PTVs or high‐dose exposure to normal tissue when the interval between PTVs is narrow.

26 July 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
JXJinrong Xie
Jinrong Xie
WQWeixiang Qi
Weixiang Qi
LCLu Cao
Lu Cao
YTYuting Tan
Yuting Tan
JHJin Huang
Jin Huang
JCJia-Yi Chen
Jia-Yi Chen
Objective: The outbreak of COVID-19 pandemic has greatly impacted on radiotherapy (RT) strategy for breast cancer patients, which might lead to increased distressing psychological symptoms. We performed a multi-center cross-section survey to investigate prevalence of fear of cancer recurrence (FCR) and predictors for FCR in patients referred to RT during pandemic.Methods: 542 patients were consecutively enrolled from three regions in China including Yangtze Delta River Region, Guangdong and Shanxi province. Patients’ characteristics were collected using an information sheet, Fear of progression questionnaire-short form, Hospital Anxiety/Depression Scale and EORTC QLQ-C30. The hierarchical multiple regression models were performed.Results: 488 patients with complete data were eligible. The RT strategy was affected in 265 (54.3%) patients, including 143 with delayed RT initiation, 66 believing to have delayed RT initiation but actually not, 24 with RT interruptions, 19 shifting to local hospitals for RT and the remaining 13 influenced on both RT schedule and hospital level. The model explained 59.7% of observed variances in FCR (p<0.001) and showed that influence of RT strategy had significantly impacted on FCR (△R2 = 0.01, △F=2.966, p=0.019). Hospitals in Shanxi province (β=-0.117, p=0.001), emotional function (β=-0.19, p<0.001), social function (β=-0.111, p=0.006), anxiety (β=0.434, p<0.001) and RT interruption (β=0.071, p=0.035) were independent predictors.Conclusions: RT strategy for breast cancer patients was greatly influenced during pandemic. RT interruption is an independent predictor for high FCR. Our findings emphasize the necessity to ensure continuum of RT, and efforts should be taken to alleviate FCR through psychological interventions.

5 January 2022 in Applied Radiation and Isotopes
Verified
Journal Article
Closed access
SDSong Duan
Song Duan
CLChengwen Li
Chengwen Li
JSJuntian Shi
Juntian Shi
YMYujia Ma
Yujia Ma
XZXingxing Zhang
Xingxing Zhang
XHXiaobo Huang
Xiaobo Huang

1 July 2019 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
XLXiao-Wen Lan
Xiao-Wen Lan
GWGe Wen
Ge Wen
ZHZhen He
Zhen He
JHJiang-Hua Huang
Jiang-Hua Huang
XZXue-Bin Zou
Xue-Bin Zou
XHXiaobo Huang
Xiaobo Huang
Purpose: Postoperative radiotherapy (RT) can improve survival for T1-2N1 breast cancer. However, there exists a concern whether BCS plus RT has the same or a superior therapeutic effect as that of mastectomy. In this study, we aimed to compare the long-term results between RT after BCS and postmastectomy RT in stage T1-2N1M0 breast cancer. Patients and Methods: Totally 1816 pathological stage T1-2N1M0 breast cancer patients were analyzed. The propensity score matching (PSM) method was used to select 196 pairs of patients between BCS and mastectomy receiving postoperative RT. Five-year locoregional relapse (LRR), locoregional relapse-free survival (LRFS), distant metastasis (DM), distant metastasis-free survival (DMFS), disease-free survival (DFS), breast cancer-specific survival (BCSS) were analyzed as endpoints. Results: In the whole group, significant differences were observed in all endpoints (P<0.05) between the no-RT and RT groups. For patients receiving mastectomy, DM, DMFS, DFS and BCSS rates had no differences between the two groups. For patients without RT in the multivariable analysis, the molecular subtype was associated with each endpoint (P<0.05). Age, primary tumor site, tumor size, and LVI status were significantly associated with DM. The analysis of 196 pairs of patients selected by PSM showed that BCS plus RT resulted in a significantly lower 5-year DM rate (P=0.015) and superior survival in terms of the 5-year DMFS (P=0.046), DFS (P=0.049) and BCSS (P=0.024) compared with mastectomy. Conclusions: Postoperative radiotherapy remarkably improved survival in T1-2N1M0 breast cancer but not in the mastectomy subgroup, except for LRR and LRFS. Patients with BCS plus RT had better survival compared with those with postmastectomy radiation in terms of DM, DMFS, DFS and BCSS.

30 July 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
JLJing Liu
Jing Liu
YTYuting Tan
Yuting Tan
ZBZhuofei Bi
Zhuofei Bi
SHSuning Huang
Suning Huang
NZNa Zhang
Na Zhang
XHXiaobo Huang
Xiaobo Huang
Introduction Postoperative radiotherapy in patients with breast cancer with one to three lymph node metastases, particularly within the pT1–2N1M0 cohort with a low clinical risk of local–regional recurrence (LRR), has incited a discourse surrounding personalised treatment strategies. Multigene testing for Recurrence Index (RecurIndex) model capably differentiates patients based on their level of LRR risk. This research aims to validate whether a more aggressive treatment approach can enhance clinical outcomes in N1 patients who possess a clinically low risk of LRR, yet a high RecurIndex-determined risk of LRR. Specifically, this entails postoperative whole breast irradiation combined with regional lymph node irradiation (RNI) following breast-conserving surgery or chest wall irradiation with RNI after mastectomy. Methods and analysis The RIGAIN (RecurIndex-Guided postoperative radiotherapy with or without Avoidance of Irradiation of regional Nodes in 1–3 node-positive breast cancer) Study is a multicentre, prospective, randomised, open-label, phase III clinical trial that is being conducted in China. In this study, patients with low clinical LRR risk but high RecurIndex-LRR risk are randomly assigned in a 1:1 ratio to the experimental group or the control group. In the experimental group, RNI is performed and the control group omits RNI. Efficacy and safety analyses will be conducted, enrolling a total of 540 patients (270 per group). The primary endpoint is invasive disease-free survival, and secondary endpoints include any first recurrence, LRR-free survival, distant metastasis-free survival, recurrence-free survival, overall survival, disease-free survival, breast cancer-specific mortality and assessment of patient quality of life. The study began in April 2023 and with a follow-up period of 60 months after the last participant completes radiation therapy. Ethics and dissemination The study was approved by the Ethics Committee of Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University (SYSKY-2022-097-02, V.3.1). It adheres to the Helsinki Declaration and Good Clinical Practice. Research findings will be submitted for publication in peer-reviewed journals. Trial registration number NCT04069884.